Menu
Not yet recruiting NCT06648200

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Phase II Interventional Small Cell Lung Cancer Extensive Stage Small Cell Lung Cancer Recurrent

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: JS004, Toripalimab, Etoposide, Platinum.
Who it may be relevant to
Registry conditions: Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer: a Single-center, Randomized Trial

Overview

For extensive-stage small cell lung cancer (SCLC), platinum-chemotherapy (cisplatin or carboplatin) combined with etoposide as the first-line treatment is recommended. However, the recurrence rate is extremely high after the initial first-line treatment. For those who relapse or progress within more than six minths after the end of the-first-line treatment, chose the current guideline recommendation trearment plan has the poor prognosis. A new immunotherapeutic strategy is needed to achieve better anti-tumor effects. JS004 is a new antibody targeting B and T lymphocyte attenuator (BTLA), which restrains immune cells; function and leads to immune escape of tumor cells. The combination of PD-1 and BTLA antibodies has shown a good therapeutic effect in solid tumors. This trial aims to investigate the efficacy and safety of the therapeutic regimen of toripalimab and JS004 combined with platinum-based doublet chemotherapy in extensive-stage SCLC or relapsed within more than six months after radical treatment SCLC.

Interventions

  • Drug JS004
    Specified dose on specified days.
  • Drug Toripalimab
    Specified dose on specified days.
  • Drug Etoposide
    Specified dose on specified days.
  • Drug Platinum
    Specified dose on specified days.

Primary outcome measures

  • Progression-free survival (PFS) [Time frame: up to 60 months]
Secondary outcome measures (5)
  • Objective response rate (ORR) [Time frame: up to 30 months]
  • Treatment-related adverse event (TRAE) [Time frame: Up to 30 months]
  • Overall survival (OS) [Time frame: up to 60 months]
  • Health related quality of life (HRQol)：EORTC-QLQ-C30 [Time frame: up to 5 months]
  • Health related quality of life (HRQol)：LC13 [Time frame: up to 5 months]

Eligibility criteria

Inclusion criteria

  • The patient shall sign the Informed Consent Form;
  • Aged 18 ≥ years;
  • Histological or cytological diagnosis of SCLC by needle biopsy or EBUS, and extensive stage or recurrent confirmed by imageological examinations or relapsed within more than six months after radical treatment SCLC;
  • Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1;
  • Life expectancy is at least 12 weeks;
  • At least 1 measurable lesion according to RECIST 1.1;
  • Patients with good function of other main organs (liver, kidney, blood system, etc.);
  • Fertile female patients must voluntarily use effective contraceptives from the start of the trial to within 30 days after its completion, and urine or serum pregnancy test results within 7 days prior to enrollment are negative;
  • Unsterilized male patients must voluntarily use effective contraception during the trial period and for 30 days after its conclusion.

Exclusion criteria

  • Patients with a malignancy other than SCLC within five years prior to the start of this trial;
  • Participants with any unstable systemic disease (including uncontrolled hypertension, severe arrhythmia, etc.);
  • With activate or suspectable autoimmune disease, or autoimmune paracancer syndrome requiring systemic treatment;
  • Participants who are allergic to the test drug or any auxiliary materials;
  • Participants with active hepatitis B, hepatitis C or HIV;
  • Participants with Interstitial lung disease currently;
  • Pregnant or lactating women;
  • Any malabsorption;
  • Participants suffering from nervous system diseases or mental diseases that cannot cooperate;
  • Other factors that researchers think it is not suitable for enrollment.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

China · 1 center
  • Shanghai Pulmonary Hospital — Shanghai

Identifiers

NCT: NCT06648200 · LungMate-031

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗